Amanda Nickles Fader
Baltimore gynaecologic oncologist who led the trial showing that adding trastuzumab to chemotherapy helps women with HER2-positive uterine serous carcinoma, an aggressive form of endometrial cancer.
Overview
Amanda Nickles Fader is a gynaecologic oncologist at Johns Hopkins. She was first author of the 2018 Journal of Clinical Oncology report of the randomised phase 2 trial in which adding trastuzumab to carboplatin and paclitaxel lengthened progression-free survival in advanced or recurrent HER2/neu-positive uterine serous carcinoma, a result that entered guidelines. Her research also covers minimally invasive surgery and rare gynaecological cancers.
Similar pages
not linked directly; found by shared links- PersonShannon N. Westin
Shares Endometrial cancer and the tags endometrial, gynaecological, trialist.
- PersonVicky Makker
Shares Endometrial cancer and the tags endometrial, gynaecological, trialist.
- PersonAna Oaknin
Shares Endometrial cancer and the tags endometrial, gynaecological, trialist.
- PersonRemi A. Nout
Shares Endometrial cancer and the tags endometrial, trialist.
- PersonMansoor Raza Mirza
Shares Endometrial cancer and the tags endometrial, trialist.
- PersonDavid M. Gershenson
Shares the tags gynaecological, trialist.
- PersonKrishnansu S. Tewari
Shares the tags gynaecological, trialist.
- TrialThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Shares p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer.